Bio Technology General - BTGC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (2001)	5/10/2000 1:38:00 PM
From: Jim Oravetz	Read Replies (1) of 2028

The U.S. Court of Appeals for the Federal Circuit denied Genentech Inc.'s (DNA) motion for an injunction pending the outcome of its appeal of a court decision earlier this year in which a Genentech patent relating to a method for producing recombinant human growth hormone was found to be invalid. In a press release Wednesday, Bio-Technology General Corp. (BTGC) said the court decision brings it one step closer to the commercialization of its human growth hormone product in the U.S. As reported in January, Bio-Technology has been involved in a lengthy battle to get its growth hormone product on the market. Bio-Technology has been arguing that competitor Genentech's patent on the drug isn't valid, which a federal judge upheld. Bio-Technology received Food and Drug Administration approval to market its drug, Bio-Tropin, in 1995. The small biotech firm hasn't been able to launch the drug in the U.S., however, because of a patent-infringement lawsuit brought by market leader Genentech. The Appellate Court also denied Genentech's motion to expedite the appeal proceedings, Bio-Technology said.snip... Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next